NCT01840527View on ClinicalTrials.gov

Utility of Novel BRAF Test for Melanoma

CompletedOBSERVATIONAL
Enrollment

220

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

March 29, 2017

Study Completion Date

September 30, 2022

Conditions
Melanoma
Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Massachusetts General Hospital

OTHER

NCT01840527 - Utility of Novel BRAF Test for Melanoma | Biotech Hunter | Biotech Hunter